Clinical Trials Logo

Clinical Trial Summary

The purpose of this phase II study was to assess the safety, tolerability and efficacy of DFV890 in participants with FCAS.


Clinical Trial Description

This was an open-label, single-arm, multiple dose, phase II study to assess safety, tolerability and clinical efficacy of DFV890 in participants with FCAS who showed evidence of inflammatory activity after the cold challenge performed during screening. The study included a screening period, a treatment period and a follow-up period. ;


Study Design


Related Conditions & MeSH terms

  • Cryopyrin-Associated Periodic Syndromes
  • Familial Cold Autoinflammatory Syndrome
  • Syndrome

NCT number NCT04868968
Study type Interventional
Source Novartis
Contact
Status Completed
Phase Phase 2
Start date September 20, 2021
Completion date May 5, 2023

See also
  Status Clinical Trial Phase
Completed NCT00991146 - Efficacy and Safety Study of Canakinumab Administered for 6 Months (24 Weeks) in Japanese Patients With Cryopyrin-associated Periodic Syndromes Followed by an Extension Phase Phase 3
Completed NCT01302860 - Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease Phase 3
Completed NCT00685373 - Efficacy and Safety of ACZ885 in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease Phase 3
Active, not recruiting NCT00887939 - Pathogenesis of Physical Induced Urticarial Syndromes
Completed NCT01576367 - Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease Phase 3